Latest News
Group behind one of biggest Canadian biotech takeovers unveils latest addition to Vancouver’s teeming life sciences sector
Morning Markets March E-Mini S&P 500 futures (ESH24 ) are up +0.35%, and March Nasdaq 100 E-Mini futures (NQH24 ) are up +0.57%, both at new all-time nearest-futures highs. Stock index futures this morning are moderately higher on optimism in the U.S. economic outlook and expectations for solid company earnings....
Ionis to hold third quarter 2023 financial results webcast
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, November 2nd at 11:30 a.m. Eastern...
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
With experienced commercial team in place, Ionis poised to independently bring steady cadence of potentially transformational RNA-targeted medicines to...
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that The Journal of the American Medical Association (JAMA) published positive...
Ionis to host investor and analyst day event
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host an investor and analyst day on Wednesday, October 4. The event...
Ionis to present at upcoming investor conferences
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor...
Ionis reports second quarter 2023 financial results
/PRNewswire/ -- – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the second quarter of 2023. Financial...
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered a collaboration and license agreement with Novartis for the...
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular...
September S&P 500 futures (ESU23) are up +0.11%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.09% this morning as market participants geared up for more corporate earnings results while also looking ahead to Friday’s nonfarm payrolls report.
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it has expanded its existing collaboration with AstraZeneca to include exclusive...
Ionis to hold second quarter 2023 financial results webcast
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, August 9th at 11:30 a.m. Eastern Time...
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
/PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced positive topline, 85-week data from the Phase 3 NEURO-TTRansform study in patients with...
Ionis to present at upcoming investor conference
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at TD Cowen's 2nd Annual RNA...
New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
/PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA®...
Ionis prices private placement of convertible senior notes
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior...
Ionis announces proposed private placement of convertible notes
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0...
Ionis announces positive donidalorsen late-stage clinical progress in HAE
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive clinical progress with donidalorsen, its late-stage investigational...
Ionis to host 2023 virtual Annual Meeting of Stockholders
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2023 virtual Annual Meeting of Stockholders...